To study the efficacy and safety of intravaginal CO2 laser versus intravaginal Er:YAG laser and sham application in alleviating genitourinary symptoms in patients receiving an aromatase inhibitor as adjuvant treatment of breast cancer
a history of breast cancer
premenopausal at diagnosis of breast cancer
using AI as an adjuvant treatment
moderate to severe symptoms of GSM (VAS ≥ 4/10)
Not willing to abstain from vaginal intercourse for 1 week following laser therapy
Use of non-hormonal vaginal preparations within the last 6 weeks before inclusion
Use of hormonal therapy within 6 months prior to inclusion (systemic or local)
Acute urinary or genital tract infections